AI assistant
Denali Therapeutics Inc. — Director's Dealing 2021
Aug 5, 2021
31637_dirs_2021-08-04_69ace9a4-e73f-4c22-9b8f-edf3b156896c.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Denali Therapeutics Inc. (DNLI)
CIK: 0001714899
Period of Report: 2021-08-02
Reporting Person: Watts Ryan J. (Director, President and CEO)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2021-08-02 | Common Stock | S | 8543 | $50.80 | Disposed | 2183866 | Indirect |
| 2021-08-02 | Common Stock | S | 9790 | $51.94 | Disposed | 2174076 | Indirect |
Holdings (Non-Derivative)
| Security | Shares | Ownership |
|---|---|---|
| Common Stock | 156691 | Direct |
Footnotes
F1: The sales reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan.
F2: The sale price reported in column 4 of Table I represents the weighted average sale price of the shares ranging from $50.42 to $51.41 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
F3: The shares are held of record by the Watts Family 2015 Trust dated July 7, 2015, for which the Reporting Person serves as trustee.
F4: The sale price reported in column 4 of Table I represents the weighted average sale price of the shares ranging from $51.42 to $52.405 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
F5: Includes 156,691 restricted stock units.